Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as a tablet for oral use. It belongs to the dihydropyridine class and is prescribed to lower elevated blood pressure in adult patients with hypertension through vascular smooth muscle relaxation.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable delivery across global markets. Our supply chain adheres to stringent standards to ensure product integrity from manufacturing to end‑user.

Lacidipine acts on the calcium‑channel pathway to manage high blood pressure.

- Hypertension: Reduces systolic and diastolic blood pressure in patients with primary hypertension. - Essential hypertension: Provides long‑acting blood pressure control when other agents are insufficient. - Isolated systolic hypertension: Lowers elevated systolic pressure in older adults.

Adverse reactions may occur with Lacipil use.

Common Side Effects: - Headache: Mild to moderate intensity. - Flushing: Transient warmth and redness of the skin. - Peripheral edema: Swelling of the ankles or lower legs. - Dizziness: Especially upon standing quickly.

Serious or Rare Side Effects: - Severe hypotension: Marked drop in blood pressure requiring medical attention. - Angio‑edema: Swelling of the face, lips, or throat. - Hepatic dysfunction: Elevated liver enzymes or jaundice.

Before prescribing Lacipil, clinicians should consider several safety aspects. - Concomitant antihypertensives: Monitor for additive blood‑pressure lowering effects. - Cardiovascular disease: Use cautiously in patients with recent myocardial infarction. - Liver impairment: Dose adjustment may be required. - Elderly patients: Start at the lowest effective dose and titrate slowly. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Lacidipine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Can increase lacidipine plasma levels, raising risk of hypotension. - Grapefruit juice: Enhances absorption and may lead to excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely):\n- Other calcium‑channel blockers: May cause additive vasodilatory effects. - Beta‑blockers: Combined use can intensify heart‑rate slowing. - Diuretics: May increase the risk of electrolyte imbalance and orthostatic hypotension.